### Guideline Page and Request

| External request: Submission from Pfizer requesting the addition of gemtuzumab ozogamicin for the treatment of pediatric patients with newly diagnosed and relapsed/refractory AML. | The panel consensus was this request was outside of the scope of the Guidelines recommendations. | 0 | 14 | 0 | 13 |

| AML-1 | External request: Submission from Celgene requesting the addition of a recommendation to test patients for an IDH-2 mutation as it may assist in identifying appropriate treatment options, including recently approved IDH-2 inhibitor, enasidenib. | Based on the data in the noted references, the panel consensus supported the addition of IDH-2 testing to the evaluation of patients with acute leukemia. See Submission for references. | 14 | 0 | 0 | 13 |

<p>| AML-2 | Internal request: Institutional request to remove the following regimens as induction treatment options for patients with low risk acute promyelocytic leukemia (APL).  • Induction: ATRA + daunorubicin + cytarabine  Consolidation: Arsenic trioxide + ATRA + daunorubicin  • Induction: ATRA + daunorubicin + cytarabine  Consolidation: Daunorubicin + cytarabine | The panel consensus supported the removal of the noted regimens as induction treatment options for patients with low risk APL. | 14 | 0 | 0 | 13 |</p>
<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| AML-4, AML-5, AML-7      | External request: Submission from Pfizer requesting the addition of gemtuzumab ozogamicin in combination with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) for the treatment of adult patients with newly diagnosed APL who have high risk disease. (see submission for detailed request) Based on the data in the noted references, the panel consensus supported the addition of the following induction treatment option for patients with high risk APL.  
  - ATRA + arsenic trioxide + gemtuzumab ozogamicin  This is a category 2A recommendation  
See Submission for references. | 14 0 0 13 |
| AML-8, AML-11, AML-12, AML-14, AML-15, AML-F | External request: Submission from Pfizer requesting the addition of gemtuzumab ozogamicin in combination with chemotherapy or as a single agent for newly diagnosed AML and as a single agent for relapsed/refractory CD33-positive AML. (see submission for detailed request) Based on the data in the noted references, the panel consensus supported the addition of the following induction/post-remission treatment option for patients <60 y with CD33-positive AML.  
  - Cytarabine + daunorubicin + gemtuzumab ozogamicin  This is a category 2A recommendation  
Based on the data in the noted references, the panel consensus supported the addition of the following induction/post-remission treatment option for patients ≥60 y with CD33-positive AML.  
  - Cytarabine + daunorubicin + gemtuzumab ozogamicin  This is a category 2A recommendation  
Based on the data in the noted references, the panel consensus supported the addition of the following induction/post-remission treatment option for patients ≥60 y with CD33-positive AML who are not candidates for intensive remission induction therapy or decline intensive therapy.  
  - Gemtuzumab ozogamicin  This is a category 2A recommendation  
Based on the data in the noted references, the panel consensus supported the addition of the following treatment option for patients with CD33-positive relapsed/refractory AML.  
  - Gemtuzumab ozogamicin  This is a category 2A recommendation  
See Submission for references. | 14 0 0 13 |
### External request: Submission from Jazz Pharmaceuticals requesting the consideration of dual-drug liposomal encapsulation of daunorubicin and cytarabine for the treatment of AML. (see submission for detailed request)

#### Panel Discussion/References

Based on the data in the noted references, the panel consensus supported the addition of the following induction/post-remission treatment option for patients <60 y with cytotoxic therapy-related AML other than core binding factory (CBF)/APL or patients with antecedent MDS/CMML or cytogenetic changes that are consistent with MDS.

- Dual-drug liposomal encapsulation of daunorubicin and cytarabine
  
  This is a category 2B recommendation

Based on the data in the noted references, the panel consensus supported the addition of the following induction/post-remission treatment option for patients ≥60 y with cytotoxic therapy-related AML or patients with antecedent MDS/CMML or cytogenetic changes that are consistent with MDS.

- Dual-drug liposomal encapsulation of daunorubicin and cytarabine
  
  This is a category 1 recommendation

Based on the data in the noted references, the panel consensus did not support the addition of the following treatment option for patients with relapsed/refractory AML.

- Dual-drug liposomal encapsulation of daunorubicin and cytarabine

See Submission for references.

#### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>3</td>
<td>1</td>
<td>13</td>
</tr>
<tr>
<td>14</td>
<td>0</td>
<td>0</td>
<td>13</td>
</tr>
<tr>
<td>1</td>
<td>13</td>
<td>0</td>
<td>13</td>
</tr>
</tbody>
</table>
### Guideline Page and Request

**AML-12, AML-15, AML-F**  
External request: Submission from Celgene requesting the addition of enasidenib as a treatment option for relapsed/refractory AML with mutated IDH-2 disease.

### Panel Discussion/References

Based on the data in the noted references, the panel consensus supported the addition of the following induction/post-remission treatment option for patients ≥60 y with IDH-2 mutated AML who are not candidates for intensive remission induction therapy or decline intensive therapy.

- **Enasidenib**  
  This is a category 2A recommendation

Based on the data in the noted references, the panel consensus supported the addition of the following treatment option for patients with IDH-2 mutated relapsed/refractory AML.

- **Enasidenib**  
  This is a category 2A recommendation

See Submission for references.

### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>0</td>
<td>0</td>
<td>13</td>
</tr>
</tbody>
</table>

14
14
0
0
13
13